Med2Date — Clinical Guidelines
Home Oncology Opioid Conversion & Morphine Equivalence

Opioid Conversion & Morphine Equivalence

Last updated 31 May 2026 · Oncology clinical guideline

📋 Key Information Summary

📋
  • Opioid conversion (opioid switching) is the process of changing from one opioid to another using equianalgesic dose ratios, with oral morphine as the reference standard.
  • Always apply a dose-reduction (typically 25–50%) when converting between opioids due to incomplete cross-tolerance — this is a critical safety measure to prevent fatal overdose.
  • Oral morphine 30 mg ≡ IV morphine 10 mg ≡ oral oxycodone 20 mg ≡ transdermal fentanyl 12 mcg/h (72-hour patch) ≡ oral hydromorphone 6 mg (approximate equianalgesic ratios).
  • Parenteral-to-oral morphine conversion ratio is 1:3 (e.g., IV morphine 10 mg = oral morphine 30 mg).
  • Methadone conversions are non-linear and require specialist supervision — never convert methadone using simple ratio tables due to variable NMDA-receptor pharmacology and long half-life.
  • In renal impairment (eGFR <30 mL/min), morphine and codeine are contraindicated; switch to fentanyl (preferred), hydromorphone (with caution), or oxycodone (reduced dose).
  • In hepatic impairment, reduce opioid starting doses by 50–75% and extend dosing intervals; avoid codeine entirely.
  • Breakthrough (rescue) dose = 10–15% of the total 24-hour opioid dose, given every 1–2 hours PRN (maximum 4–6 doses per 24 hours).
  • When switching to a transdermal fentanyl patch from oral morphine, calculate the 24-hour morphine equivalent, divide by 3 to obtain the hourly fentanyl rate, and apply a further 25% dose reduction.
  • Naloxone (Narcan®) must be available wherever opioid conversions are performed; monitor for respiratory depression for at least 24 hours post-conversion.
  • Document every conversion clearly in the patient's medication chart, including the calculated equianalgesic dose, reduction applied, and the new regimen.
  • Oxycodone-to-morphine ratio is approximately 1:1.5 (oral oxycodone 20 mg ≡ oral morphine 30 mg); some references report 2:3.
  • ATSI patients may have reduced access to specialist palliative care; use simplified conversion charts and telehealth support when available.

Introduction & Australian Context

Opioid conversion — also termed opioid rotation or opioid switching — is a core competency in oncology pain management. It involves substituting one opioid analgesic for another using published equianalgesic dose ratios, with oral morphine serving as the reference agent. Accurate conversion is essential to maintain analgesia while minimising the risk of toxicity from incomplete cross-tolerance between agents.

In Australia, opioid use for cancer pain is widespread: the Pharmaceutical Benefits Scheme (PBS) data show that approximately 60,000–80,000 Australians receive PBS-subsidised strong opioids annually for malignant pain, with morphine, oxycodone, and fentanyl patches being the most commonly dispensed formulations. The Australian Institute of Health and Welfare (AIHW) reports that opioid-related hospitalisations continue to rise, underscoring the importance of safe prescribing practices, particularly during opioid switches.

This guideline provides a practical framework for opioid conversion in adult oncology patients, covering equianalgesic principles, specific drug conversion tables, adjustment for organ impairment, and breakthrough dose calculation. It aligns with the Therapeutic Guidelines (eTG) recommendations, Cancer Council Australia palliative care guidelines, and the Faculty of Pain Medicine (ANZCA) position statements on opioid stewardship.

⚠️
Critical safety warning: All published equianalgesic ratios are approximate. Individual patient response varies with receptor pharmacology, prior opioid exposure, renal/hepatic function, and genetic polymorphisms (e.g., CYP2D6 for codeine). Always apply a dose-reduction of 25–50% when converting and titrate to effect. Never use equianalgesic tables for methadone conversion without specialist oversight.

Opioid Equivalence Principles

Equianalgesic dose tables define the dose of one opioid that provides approximately the same analgesic effect as a reference dose of another. These tables are derived from single-dose studies in opioid-naïve populations and must be applied cautiously in patients on chronic opioid therapy.

Fundamental Principles

  • Incomplete cross-tolerance: Tolerance to one opioid does not fully transfer to another. A dose reduction of 25–50% (typically 25% for same-class switches, 50% when switching to or from methadone) is mandatory to account for this phenomenon.
  • Route of administration matters: Bioavailability differs significantly between oral, parenteral, transdermal, and sublingual routes. Equianalgesic ratios are route-specific.
  • Calculate the 24-hour total: Before converting, sum all opioid doses received in the preceding 24 hours, including breakthrough doses that were actually administered.
  • Round doses sensibly: After conversion, round to the nearest available tablet or patch strength to simplify administration.
  • One opioid at a time: Avoid concurrent administration of the old and new opioid during the conversion period unless deliberately overlapping during patch application (allow 12–18 hours of overlap for fentanyl patches).
  • Reassess frequently: Monitor pain scores, sedation level, and respiratory rate at least every 4 hours for the first 24–48 hours after any opioid switch.

When to Consider Opioid Rotation

Indication Details
Dose-limiting toxicity Unacceptable side-effects (e.g., myoclonus, severe constipation, cognitive impairment) despite inadequate analgesia at current dose
Inadequate analgesia Escalating doses with diminishing pain relief (opioid tolerance or opioid-induced hyperalgesia)
Organ impairment Worsening renal or hepatic function requiring a safer agent (e.g., stopping morphine in renal failure)
Route change Patient can no longer swallow (enteral route) → switch to subcutaneous, transdermal, or sublingual
Practical / patient preference Simplifying regimen (e.g., converting to a fentanyl patch for convenience)

Morphine Equivalence Doses

The following equianalgesic table is based on oral morphine 30 mg as the reference standard. These ratios are widely used in Australian practice and align with eTG, Cancer Council Australia, and Palliative Care Australia recommendations.

Oral Equianalgesic Doses (Reference: Oral Morphine 30 mg)

Opioid Approximate Equianalgesic Dose Oral:Parenteral Ratio Notes
Morphine (oral) 30 mg 3:1 (oral:IV) Reference standard
Morphine (IV/SC) 10 mg — SC bioavailability ≈ 90% of IV
Oxycodone (oral) 20 mg 2:1 (oral:IV) Ratio morphine:oxycodone ≈ 1.5:1
Oxycodone (IV) 10 mg — Not PBS-listed for IV use
Hydromorphone (oral) 6 mg 5:1 (oral:IV) Morphine:hydromorphone ≈ 5:1 oral
Hydromorphone (SC/IV) 1.5 mg — Preferred in renal impairment (caution)
Fentanyl (transdermal) 12 mcg/h patch (72 h) — Oral morphine 60 mg/24 h ≈ fentanyl 25 mcg/h patch
Fentanyl (IV/SC) 100 mcg — Short-acting; suitable for PCA and procedural sedation
Tramadol (oral) 150–200 mg — Weak opioid + SNRI; max 400 mg/day; seizure risk
Codeine (oral) 200 mg — Prodrug (CYP2D6); poor metabolisers get no effect
Methadone (oral) Variable (specialist only) 2:1 (oral:IV) Non-linear; do NOT use standard tables
🚨
Methadone conversion: Methadone equianalgesic ratios are non-linear and depend on the patient's prior opioid dose. At low morphine equivalent doses (<60 mg/24 h), the methadone:morphine ratio is approximately 1:4, but at higher doses the ratio can reach 1:12 or greater. Methadone conversions must be performed by or in consultation with a pain or palliative care specialist. The long and variable half-life (15–60 hours) adds significant risk of delayed accumulation and respiratory depression.

Parenteral Equianalgesic Doses (Reference: IV Morphine 10 mg)

Opioid (Parenteral) Equianalgesic Dose Onset Duration
Morphine IV 10 mg 5–10 min 3–4 h
Oxycodone IV 10 mg 2–5 min 3–4 h
Hydromorphone SC/IV 1.5 mg 5–15 min 3–5 h
Fentanyl IV 100 mcg 1–2 min 30–60 min
Methadone IV Variable 10–20 min 6–12+ h

How to Calculate Oral Morphine Equivalent Daily Dose (OMEDD)

1
Sum all current opioids
Calculate total dose of each opioid in 24 hours, including scheduled and PRN doses actually administered.
2
Convert each to oral morphine equivalent
Multiply each opioid's 24-hour dose by its conversion factor (see table below).
3
Sum the equivalents
Add all morphine equivalents together to obtain the total OMEDD.
4
Apply dose reduction
Reduce total by 25–50% to account for incomplete cross-tolerance.

Conversion Factors to Oral Morphine

Current Opioid Route Multiply Dose By To Get Oral Morphine Equivalent
Morphine Oral × 1 Already in OME units
Morphine IV / SC × 3 e.g., 10 mg IV × 3 = 30 mg OME
Oxycodone Oral × 1.5 e.g., 20 mg PO × 1.5 = 30 mg OME
Hydromorphone Oral × 5 e.g., 6 mg PO × 5 = 30 mg OME
Hydromorphone IV / SC × 20 e.g., 1.5 mg SC × 20 = 30 mg OME
Fentanyl Transdermal (mcg/h) × 5 (24 h OME per mcg/h) e.g., 12 mcg/h × 5 × 24 h = use step 5
Fentanyl patch Transdermal Patch rate (mcg/h) × 2 = OME mg/24 h e.g., 25 mcg/h → 50 mg OME/24 h
Codeine Oral × 0.15 e.g., 200 mg PO × 0.15 = 30 mg OME
Tramadol Oral × 0.2 e.g., 150 mg PO × 0.2 = 30 mg OME

Conversion to Fentanyl & Oxycodone

Fentanyl transdermal patches and oral oxycodone are the two most common targets for opioid rotation in Australian oncology practice. Both require specific conversion procedures that differ from simple oral-to-oral switches.

Converting Oral Morphine to Transdermal Fentanyl

⚠️
Key safety steps: (1) Calculate 24-hour oral morphine total. (2) Convert using the ratio: oral morphine 60 mg/24 h ≈ fentanyl 25 mcg/h patch. (3) Apply a 25% dose reduction for incomplete cross-tolerance. (4) Do NOT initiate fentanyl patches in opioid-naïve patients. (5) Allow 12–18 hours of overlap with the previous opioid after patch application, as fentanyl takes up to 18 hours to reach steady state.
Oral Morphine 24 h Dose Fentanyl Patch (mcg/h)
60 mg25 mcg/h
90 mg37 mcg/h (use 50 mcg/h in practice)
120 mg50 mcg/h
180 mg75 mcg/h
240 mg100 mcg/h
300 mg125 mcg/h (use two patches: 75 + 50)

Practical formula: Fentanyl patch rate (mcg/h) = [Oral morphine 24 h dose (mg) ÷ 3] × 0.75 (after 25% reduction). Round to the nearest available patch size (12, 25, 50, 75, 100 mcg/h). Note that the 12 mcg/h patch is not PBS-subsidised in all indications.

Converting to Oral Oxycodone

Oxycodone is the most commonly used alternative to morphine in Australia, with wide PBS availability in both immediate-release (Endone®, OxyNorm®) and controlled-release (OxyNorm® SR, Targin®) formulations.

💊
Oxycodone Immediate-Release
Endone® · OxyNorm® · Opioid agonist
Adult dose 5–10 mg PO every 4–6 hours PRN; titrate to effect
Conversion ratio Oral morphine : oral oxycodone ≈ 1.5 : 1 (morphine 30 mg ≡ oxycodone 20 mg)
Paediatric dose 0.1–0.2 mg/kg PO every 4–6 h (max 5 mg/dose for children <12 years)
Renal adjustment eGFR 10–50: reduce dose 50%; eGFR <10: avoid or reduce 75%
PBS status ✔ PBS General Benefit
💊
Oxycodone Controlled-Release
OxyNorm® SR · Targin® (with naloxone) · Opioid agonist
Adult dose 10–20 mg PO every 12 h (or 5 mg every 8 h); round IR dose to calculate SR
Conversion ratio Same 1.5:1 ratio as IR oxycodone; total 24 h SR dose = sum of IR doses
Renal adjustment As per IR formulation
PBS status ✔ PBS General Benefit

Converting Oxycodone to Morphine

The reverse conversion uses the ratio oral oxycodone 20 mg ≡ oral morphine 30 mg. Multiply the 24-hour oxycodone dose by 1.5 to obtain the oral morphine equivalent, then apply a 25% reduction.

Example: Patient taking oxycodone SR 40 mg every 12 hours (80 mg/24 h). Morphine equivalent = 80 × 1.5 = 120 mg OME/24 h. After 25% reduction: 120 × 0.75 = 90 mg oral morphine/24 h. This could be prescribed as morphine SR 45 mg every 12 hours (rounding to available 30 mg + 15 mg or 45 mg if available, or 30 mg every 8 h).

Other Common Conversion Scenarios

From To Method Dose Reduction
Oral morphine Oral hydromorphone Divide oral morphine dose by 5 25–50%
Oral oxycodone Oral hydromorphone Convert to OME first (×1.5), then divide by 5 25%
Transdermal fentanyl Oral morphine Patch rate (mcg/h) × 2 = OME mg/24 h 25%
Oral morphine SC morphine infusion Divide oral dose by 3 (same as IV ratio) None to 25%
Oral morphine SC fentanyl infusion Convert to OME, then use fentanyl 100 mcg IV ≡ OME 30 mg 50%

Renal/Hepatic Adjustment & Breakthrough Dosing

Opioid Use in Renal Impairment

Renal impairment significantly affects opioid pharmacokinetics. Morphine-6-glucuronide (M6G) and morphine-3-glucuronide (M3G) accumulate in renal failure, causing prolonged sedation, respiratory depression, and myoclonus. Opioid selection must be tailored to eGFR.

🚨
Morphine is contraindicated when eGFR <15 mL/min (CKD stage 5) or in acute kidney injury. Active metabolites M6G and M3G accumulate rapidly and can cause life-threatening respiratory depression. Switch to fentanyl (preferred) or hydromorphone (with caution).
Opioid eGFR 30–50 eGFR 15–29 eGFR <15 / Dialysis
Morphine Reduce dose 50%; extend interval Avoid Contraindicated
Oxycodone Reduce dose 50% Reduce dose 75% Avoid or specialist use only
Hydromorphone Reduce dose 50% Reduce dose 75% Use with extreme caution; active metabolite H3G accumulates
Fentanyl No adjustment No adjustment Preferred opioid — no active metabolites
Methadone No adjustment No adjustment Specialist use; monitor QTc
Codeine Reduce dose 50% Avoid Contraindicated
Tramadol Max 200 mg/day Max 100 mg/day Avoid

Opioid Use in Hepatic Impairment

Hepatic impairment reduces opioid clearance via cytochrome P450 metabolism (CYP3A4, CYP2D6). Oral bioavailability may paradoxically increase due to reduced first-pass metabolism. All opioids require dose reduction in significant liver disease.

Severity (Child-Pugh) Recommendation
Mild (Class A, score 5–6) Reduce starting dose by 25%; titrate cautiously
Moderate (Class B, score 7–9) Reduce starting dose by 50%; extend dosing intervals
Severe (Class C, score 10–15) Reduce starting dose by 75%; use short-acting agents only; avoid morphine and codeine

Key hepatic adjustments:

  • Codeine: Contraindicated in all grades of hepatic impairment — reduced conversion to morphine and unpredictable pharmacokinetics.
  • Fentanyl: Preferred in moderate–severe hepatic impairment due to hepatic-independent clearance, but reduce initial dose by 50% in severe disease.
  • Morphine: Bioavailability increases to nearly 100% in cirrhosis (normally 20–30%); reduce dose significantly.
  • Tramadol: Avoid in hepatic impairment due to CYP-dependent metabolism and risk of serotonin syndrome.

Breakthrough (Rescue) Dosing

Breakthrough analgesia is essential during any opioid conversion and for incident/breakthrough pain in cancer patients. The rescue dose should be calculated from the new opioid regimen.

1
Calculate total 24-hour dose of the new opioid
Sum all scheduled doses of the new opioid over 24 hours.
2
Take 10–15% of the 24-hour dose
This becomes the single breakthrough dose. Use 10% initially; increase to 15% if inadequate.
3
Administer every 1–2 hours PRN
Oral IR opioids can be given every 1–2 hours; SC/IV every 15–30 minutes. Limit to 4–6 doses per 24 hours.
4
Reassess and adjust
If >3 breakthrough doses are required in 24 hours, increase the background opioid dose by 30–50% and recalculate the breakthrough dose.

Breakthrough dose example: Patient on oral morphine SR 60 mg every 12 hours (120 mg/24 h). Breakthrough dose = 120 × 0.10 = 12 mg oral morphine IR. Use Endone® 10 mg or morphine IR (Ordine®) 10 mg orally every 1–2 hours PRN.

💊
Morphine Immediate-Release
Ordine® oral liquid · Sevredol® tablets · Opioid agonist
Adult breakthrough dose 5–10 mg PO every 1–2 h PRN (or 2.5–5 mg SC every 1–2 h)
Paediatric dose 0.2–0.5 mg/kg PO every 3–4 h PRN; 0.1 mg/kg SC/IV every 2–4 h
Renal adjustment eGFR <30: avoid; use fentanyl instead
PBS status ✔ PBS General Benefit
💊
Fentanyl Sublingual Tablet
Abstral® · Effentora® (buccal) · Opioid agonist
Adult breakthrough dose 100–200 mcg sublingual every 4 h PRN; titrate from 100 mcg
Indication Breakthrough cancer pain in opioid-tolerant patients only
Onset ~10 minutes (rapid transmucosal absorption)
PBS status ⚠ PBS Authority Required

Monitoring During Opioid Conversion

0–4 hours
Assess sedation score (MOAA/S or Pasero), respiratory rate, pain score (NRS 0–10), and haemodynamics every 30–60 minutes after first dose of new opioid.
4–24 hours
Monitor vital signs every 2–4 hours. Assess for signs of toxicity: myoclonus, pinpoint pupils, Cheyne-Stokes respiration, excessive sedation.
24–72 hours
Continue 4-hourly monitoring. Titrate new opioid to achieve NRS pain score ≤4. Assess bowel function and initiate laxatives if not already prescribed.
>72 hours
Stable patients can be stepped down to routine monitoring. Continue pain assessment at each clinical encounter.
✅
Naloxone availability: Ensure naloxone (Narcan®) injection 400 mcg IV/IM/SC is immediately accessible whenever opioid conversions are performed. For suspected opioid overdose: naloxone 400 mcg IV, repeated every 2–3 minutes to a maximum of 2 mg. In opioid-tolerant patients, dilute and titrate carefully to avoid precipitating severe withdrawal.

Special Populations

🤰 Pregnancy
Morphine Category C. Can be used in pregnancy for severe cancer pain under specialist supervision. Neonatal withdrawal syndrome expected with chronic use — plan for neonatal monitoring post-delivery.
Oxycodone Category C. Similar safety profile to morphine. Avoid prolonged use near delivery (risk of neonatal respiratory depression).
Fentanyl Category C. Transdermal may be preferred for steady-state delivery. Neonatal monitoring required.
Codeine Contraindicated — risk of neonatal respiratory depression via breast milk; unpredictable CYP2D6 metabolism.
👶 Paediatrics
Morphine First-line strong opioid for paediatric cancer pain. Oral: 0.2–0.5 mg/kg every 4 h. IV/SC: 0.1 mg/kg every 2–4 h. Neonates: reduce dose by 50% and extend interval.
Oxycodone Alternative when morphine not tolerated. 0.1–0.2 mg/kg PO every 4–6 h. Limited paediatric safety data compared to morphine.
Fentanyl Transdermal patches generally not recommended in children <12 years. IV/SC fentanyl used in paediatric palliative care settings.
Codeine Contraindicated in all children <12 years and in children 12–18 years post-tonsillectomy/adenoidectomy (TGA, 2015).
👴 Elderly (≥65 years)
General Start at 25–50% of standard adult dose. Increased sensitivity due to reduced renal clearance, lean body mass, and hepatic metabolism. Higher risk of falls, confusion, and respiratory depression.
Morphine Use IR formulations to assess response before switching to SR. Avoid in eGFR <30.
Fentanyl patch Useful for adherence but beware altered pharmacokinetics in cachectic patients (reduced subcutaneous fat affects absorption).
🫘 Renal Impairment
Preferred Fentanyl (no active metabolites) — first-line in severe renal impairment. Methadone — no renal adjustment needed but requires specialist oversight.
Avoid Morphine (eGFR <30), codeine (eGFR <30), pethidine (toxic normeperidine metabolite). See Renal Adjustment table above.
🫁 Hepatic Impairment
Preferred Fentanyl (reduced doses in severe disease). Short-acting agents with titratable dosing.
Avoid Codeine (unpredictable metabolism), tramadol (serotonin syndrome risk). See Hepatic Adjustment table above.
🛡️ Immunocompromised
General No specific opioid restrictions, but immunocompromised patients are often on multiple interacting medications. Check CYP3A4 interactions with azole antifungals (↑ fentanyl levels) and avoid tramadol (seizure risk with carbapenems).

Aboriginal and Torres Strait Islander Health Considerations

Aboriginal and Torres Strait Islander Health

Aboriginal and Torres Strait Islander peoples experience a disproportionate burden of cancer, with incidence rates approximately 1.5 times higher than non-Indigenous Australians and significantly lower five-year survival rates (AIHW, 2023). Pain management in this population requires culturally safe approaches that acknowledge the impact of historical trauma, systemic barriers, and geographic isolation on opioid access and adherence.

Remote & rural access
Many ATSI patients live in remote communities with limited access to specialist palliative care, pharmacy services, and opioid dispensing. Telehealth palliative care consultations via the Australian Government's telehealth programme can support remote opioid prescribing. Coordinate with Remote Area Nurses (RANs) and Aboriginal Health Workers (AHWs) for medication monitoring.
Cultural safety
Engage Aboriginal Liaison Officers (ALOs) and incorporate yarning-based communication. Avoid overly complex conversion regimens — use simplified dosing charts with pictorial aids. Respect sorry business and kinship obligations that may affect medication adherence and appointment attendance.
Health literacy
Provide medication instructions in plain English and, where available, in local Indigenous language. Use the Australian Commission on Safety and Quality in Health Care (ACSQHC) health literacy resources. Confirm understanding of breakthrough dosing with teach-back methodology.
Medication storage
In remote communities, opioid storage poses safety challenges. Coordinate secure storage arrangements with community health centres. Transdermal fentanyl patches may be preferable to liquid morphine for some settings due to reduced diversion risk, but must be disposed of safely after use.
Pharmaceutical Benefits
Ensure ATSI patients access Closing the Gap PBS co-payment measures. Eligible patients can obtain PBS medicines at a reduced co-payment or free. Register patients under the Indigenous health exemption to reduce out-of-pocket costs for opioid medications.
Renal considerations
ATSI peoples have higher rates of chronic kidney disease (CKD) — approximately 2.3 times the non-Indigenous rate. Screen eGFR before opioid conversion and select renal-appropriate agents (fentanyl preferred in CKD stage 4–5). Use pathology results from the local Aboriginal Medical Service where available.

📚 References

  1. 1. Australian Institute of Health and Welfare (AIHW). Alcohol, tobacco & other drugs in Australia: opioid harm in Australia. Cat. no. PHE 269. Canberra: AIHW; 2023.
  2. 2. Mercadante S, Bruera E. Opioid switching: a systematic and critical review. Cancer Treatment Reviews. 2006;32(4):304–315.
  3. 3. Faculty of Pain Medicine, Australian and New Zealand College of Anaesthetists (FPM ANZCA). Statement on the use of opioid analgesics in adults with chronic non-cancer pain. Melbourne: ANZCA; 2022.
  4. 4. Cancer Council Australia. Cancer pain management in adults: clinical guidelines. Sydney: Cancer Council Australia; 2021.
  5. 5. Australian Government Department of Health. Pharmaceutical Benefits Schedule — opioid analgesics. Canberra: Commonwealth of Australia; 2024. Available at: pbs.gov.au.
  6. 6. King S, Forbes K, Hanks GW, Ferro CJ, Chambers EJ. A systematic review of the use of opioid dose conversion equianalgesic ratios to support clinical decision making. Journal of Pain and Symptom Management. 2011;42(3):449–462.
  7. 7. Palliative Care Australia. National Palliative Care Standards. 5th ed. Canberra: Palliative Care Australia; 2018.
  8. 8. Dean M. Opioids in renal failure and dialysis patients. Journal of Pain and Symptom Management. 2004;28(5):497–504.
  9. 9. Ratajczak A, Glinka K, Procyk M, et al. Opioids in hepatic impairment — a systematic review. Pharmaceuticals. 2021;14(11):1161.
  10. 10. Therapeutic Goods Administration (TGA). Codeine: changes to over-the-counter access. Canberra: Australian Government Department of Health; 2018.
  11. 11. Australian Commission on Safety and Quality in Health Care (ACSQHC). Australian Atlas of Healthcare Variation — opioid prescribing. Sydney: ACSQHC; 2021.
  12. 12. Australian Institute of Health and Welfare (AIHW). Aboriginal and Torres Strait Islander health performance framework: summary report. Canberra: AIHW; 2023.
  13. 13. Mercadante S, Caraceni A. Conversion ratios for opioid switching in the treatment of cancer pain: a systematic review. Palliative Medicine. 2011;25(5):504–515.
  14. 14. Chou R, Cruciani RA, Fiellin DA, et al. Methadone safety: a clinical practice guideline from the American Pain Society and College on Problems of Drug Dependence. Journal of Pain. 2014;15(4):321–337.
for PBS-listed medicines at participating pharmacies.
Cultural safety
Engagement with Aboriginal Community Controlled Health Organisations (ACCHOs) is essential. Cultural safety training for non-Indigenous clinicians, use of Aboriginal Health Workers and Liaison Officers, and incorporation of traditional healing practices alongside Western medicine improve treatment adherence and outcomes. Avoidance of eye contact, respect for gender-sensitive examination practices, and understanding of sorry business protocols are critical elements of culturally safe care.
Medication adherence
Complex DMARD regimens with frequent monitoring requirements present adherence challenges. Long-acting depot injections (e.g., methotrexate SC) may improve adherence compared to oral regimens. Community pharmacy partnerships through the Indigenous Pharmacy Programmes improve medication management.
Specific conditions
Rheumatic heart disease (RHD) requires secondary prophylaxis with benzathine penicillin G (BPG) 1.2 MU IM every 3–4 weeks for a minimum of 10 years or until age 21 (whichever is longer). RHD registers (e.g., NT RHD Register) facilitate recall and follow-up. The Australian RHD Endgame Strategy targets elimination by 2031.
Referral pathways
Referral through ACCHOs and Aboriginal Hospital Liaison Officers (AHLOs) improves engagement. The Specialist Outreach Assistance Programme provides funded specialist visits to remote communities. NT, WA, and QLD have specific rheumatology outreach programmes targeting Indigenous communities.

📚 References

  1. 1. Australian Institute of Health and Welfare (AIHW). Autoimmune disease in Australia. Cat. no. PHE 312. Canberra: AIHW; 2023.
  2. 2. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res. 2021;73(7):924–939.
  3. 3. Fanouriakis A, Kostopoulou M, Alber K, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736–745.
  4. 4. Chung SA, Langford CA, Maz M, et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Care Res. 2021;73(11):1583–1599.
  5. 5. Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3–18.
  6. 6. Australian Technical Advisory Group on Immunisation (ATAGI). Australian Immunisation Handbook. Australian Government Department of Health; 2024. Available from: immunisationhandbook.health.gov.au.
  7. 7. Rheumatic Heart Disease Australia (RHDAustralia). The 2020 Australian guideline for prevention, diagnosis, and management of acute rheumatic fever and rheumatic heart disease. 3rd ed. Darwin: Menzies School of Health Research; 2020.
  8. 8. Pharmaceutical Benefits Scheme (PBS). PBS Schedule. Australian Government Department of Health. Available from: pbs.gov.au. Accessed 2024.
  9. 9. Agarwal S, Cunnington J, Nossent J. Autoimmune disease in Indigenous Australians: a systematic review. Int J Rheum Dis. 2021;24(12):1487–1498.
  10. 10. Pisetsky DS. Antinuclear antibody testing — misunderstood or misused? Clin Immunol. 2023;255:109717.
  11. 11. Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71(11):1771–1782.
  12. 12. Ledingham J, Deighton C; British Society for Rheumatology Standards, Audit and Guidelines Working Group. Update on the British Society for Rheumatology guidelines for prescribing TNFα blockers in adults with rheumatoid arthritis. Rheumatology. 2005;44(2):155–158.
  13. 13. National Health and Medical Research Council (NHMRC). National statement on ethical conduct in human research. Canberra: NHMRC; 2023 (updated).
for PBS-listed medicines at participating pharmacies.
Cultural safety
Engagement with Aboriginal Community Controlled Health Organisations (ACCHOs) is essential. Cultural safety training for non-Indigenous clinicians, use of Aboriginal Health Workers and Liaison Officers, and incorporation of traditional healing practices alongside Western medicine improve treatment adherence and outcomes. Avoidance of eye contact, respect for gender-sensitive examination practices, and understanding of sorry business protocols are critical elements of culturally safe care.
Medication adherence
Complex DMARD regimens with frequent monitoring requirements present adherence challenges. Long-acting depot injections (e.g., methotrexate SC) may improve adherence compared to oral regimens. Community pharmacy partnerships through the Indigenous Pharmacy Programmes improve medication management.
Specific conditions
Rheumatic heart disease (RHD) requires secondary prophylaxis with benzathine penicillin G (BPG) 1.2 MU IM every 3–4 weeks for a minimum of 10 years or until age 21 (whichever is longer). RHD registers (e.g., NT RHD Register) facilitate recall and follow-up. The Australian RHD Endgame Strategy targets elimination by 2031.
Referral pathways
Referral through ACCHOs and Aboriginal Hospital Liaison Officers (AHLOs) improves engagement. The Specialist Outreach Assistance Programme provides funded specialist visits to remote communities. NT, WA, and QLD have specific rheumatology outreach programmes targeting Indigenous communities.

📚 References

  1. 1. Australian Institute of Health and Welfare (AIHW). Autoimmune disease in Australia. Cat. no. PHE 312. Canberra: AIHW; 2023.
  2. 2. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res. 2021;73(7):924–939.
  3. 3. Fanouriakis A, Kostopoulou M, Alber K, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736–745.
  4. 4. Chung SA, Langford CA, Maz M, et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Care Res. 2021;73(11):1583–1599.
  5. 5. Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3–18.
  6. 6. Australian Technical Advisory Group on Immunisation (ATAGI). Australian Immunisation Handbook. Australian Government Department of Health; 2024. Available from: immunisationhandbook.health.gov.au.
  7. 7. Rheumatic Heart Disease Australia (RHDAustralia). The 2020 Australian guideline for prevention, diagnosis, and management of acute rheumatic fever and rheumatic heart disease. 3rd ed. Darwin: Menzies School of Health Research; 2020.
  8. 8. Pharmaceutical Benefits Scheme (PBS). PBS Schedule. Australian Government Department of Health. Available from: pbs.gov.au. Accessed 2024.
  9. 9. Agarwal S, Cunnington J, Nossent J. Autoimmune disease in Indigenous Australians: a systematic review. Int J Rheum Dis. 2021;24(12):1487–1498.
  10. 10. Pisetsky DS. Antinuclear antibody testing — misunderstood or misused? Clin Immunol. 2023;255:109717.
  11. 11. Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71(11):1771–1782.
  12. 12. Ledingham J, Deighton C; British Society for Rheumatology Standards, Audit and Guidelines Working Group. Update on the British Society for Rheumatology guidelines for prescribing TNFα blockers in adults with rheumatoid arthritis. Rheumatology. 2005;44(2):155–158.
  13. 13. National Health and Medical Research Council (NHMRC). National statement on ethical conduct in human research. Canberra: NHMRC; 2023 (updated).